Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Fosaprepitant> ?p ?o. }
Showing items 1 to 73 of
73
with 100 items per page.
- Fosaprepitant abstract "Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 and by the European Medicines Agency (EMA) on January 11 of the same year.".
- Fosaprepitant atcPrefix "A04".
- Fosaprepitant atcSuffix "AD12".
- Fosaprepitant casNumber "172673-20-0".
- Fosaprepitant casSupplemental "(dimeglumine)".
- Fosaprepitant drugbank "DB06717".
- Fosaprepitant fdaUniiCode "6L8OF9XRDC".
- Fosaprepitant iupacName "[3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid".
- Fosaprepitant pubchem "219090".
- Fosaprepitant thumbnail Fosaprepitant.svg?width=300.
- Fosaprepitant wikiPageID "16307876".
- Fosaprepitant wikiPageRevisionID "545182686".
- Fosaprepitant atcPrefix "A04".
- Fosaprepitant atcSuffix "AD12".
- Fosaprepitant bioavailability "n/a".
- Fosaprepitant c "23".
- Fosaprepitant casNumber "172673".
- Fosaprepitant chembl "1199324".
- Fosaprepitant drugbank "DB06717".
- Fosaprepitant eliminationHalfLife "46800.0".
- Fosaprepitant f "7".
- Fosaprepitant h "22".
- Fosaprepitant hasPhotoCollection Fosaprepitant.
- Fosaprepitant iupacName "[3-{[-2-[-1-[3,5-bisphenyl] ethoxy]-3-morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid".
- Fosaprepitant kegg "D06597".
- Fosaprepitant legalUs "Rx-only".
- Fosaprepitant licenceEu "Ivemend".
- Fosaprepitant licenceUs "Fosaprepitant".
- Fosaprepitant medlineplus "a604003".
- Fosaprepitant metabolism "To aprepitant".
- Fosaprepitant molecularWeight "614.406".
- Fosaprepitant n "4".
- Fosaprepitant o "6".
- Fosaprepitant p "1".
- Fosaprepitant pregnancyUs "B".
- Fosaprepitant proteinBound ">95%".
- Fosaprepitant pubchem "219090".
- Fosaprepitant routesOfAdministration Intravenous_therapy.
- Fosaprepitant unii "6".
- Fosaprepitant verifiedfields "changed".
- Fosaprepitant verifiedrevid "416448532".
- Fosaprepitant watchedfields "changed".
- Fosaprepitant subject Category:Antiemetics.
- Fosaprepitant subject Category:Morpholines.
- Fosaprepitant subject Category:NK1_receptor_antagonists.
- Fosaprepitant subject Category:Organofluorides.
- Fosaprepitant subject Category:Phosphoramidates.
- Fosaprepitant subject Category:Prodrugs.
- Fosaprepitant subject Category:Triazoles.
- Fosaprepitant type Adversary109773245.
- Fosaprepitant type CausalAgent100007347.
- Fosaprepitant type LivingThing100004258.
- Fosaprepitant type NK1ReceptorAntagonists.
- Fosaprepitant type Object100002684.
- Fosaprepitant type Organism100004475.
- Fosaprepitant type Person100007846.
- Fosaprepitant type PhysicalEntity100001930.
- Fosaprepitant type Whole100003553.
- Fosaprepitant type YagoLegalActor.
- Fosaprepitant type YagoLegalActorGeo.
- Fosaprepitant type Drug.
- Fosaprepitant type DrugProduct.
- Fosaprepitant type FunctionalSubstance.
- Fosaprepitant comment "Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 and by the European Medicines Agency (EMA) on January 11 of the same year.".
- Fosaprepitant label "Fosaprepitant".
- Fosaprepitant label "福沙匹坦".
- Fosaprepitant sameAs m.03wglr0.
- Fosaprepitant sameAs Q5473324.
- Fosaprepitant sameAs Q5473324.
- Fosaprepitant sameAs Fosaprepitant.
- Fosaprepitant wasDerivedFrom Fosaprepitant?oldid=545182686.
- Fosaprepitant depiction Fosaprepitant.svg.
- Fosaprepitant isPrimaryTopicOf Fosaprepitant.